Skip to main content

Table 1 Demographic and clinical characteristics at baseline and 1-year follow-up

From: Copy number variation at the 22q11.2 locus influences prevalence, severity, and psychiatric impact of sleep disturbance

  Typically developing control subjects 22q11.2 deletion carriers 22q11.2 duplication carriers
Baseline
ntotal 88 107 42
nSIPS 74 85 34
 Age, years (SD) 14.65 (7.4) 14.56 (8.0) 16.26 (13.1)
 Age range, years 6–45 6–43 5–49
 Males, n (%) 41 (47.1%) 53 (50.0%) 23 (54.8%)
 Non-white, n (%)a,b 27 (30.7%) 10 (9.3%) 1 (2.4%)
 Highest parental education, years (SD)c 16.78 (3.3) 17.17 (2.5) 15.41 (2.7)
 Poor sleepers, n (%)d,e 3 (3.4%) 34 (31.8%) 14 (33.3%)
 Psychosis, n (%)c,d 0 (0%) 12 (11.2%) 0 (0%)
 ASD, n (%)d,e 0 (0%) 48 (44.9%) 17 (40.5%)
 Medication, n (%)d,e
  Anti-psychotics 0 13 (12.1%) 4 (9.5%)
  Mood stabilizers 2 (2.3%) 12 (11.4%) 3(7.1%)
  Stimulants 2 (2.3%) 3 (2.9%) 6 (14.3%)
  Other medication 1 (1.1%) 8 (7.6%) 2 (4.8%)
  No medication 83 (94.3%) 69 (65.7%) 27 (64.3%)
One-year follow-up
ntotal 42 62 20
nSIPS 32 52 17
 Age, years (SD) 14.12 (5.9) 16.18 (7.2) 14.55 (9.1)
 Age range, years 7–30 7–41 6–44
 Males, n (%) 18 (43.9%) 27 (43.5%) 13 (65.0%)
 Non-white, n (%) 8 (19.0%) 9 (14.5%) 1 (5.0%)
 Highest parental education, years (SD) 17.86 (2.9) 17.00 (2.2) 15.42 (3.1)
 Poor sleepers, n (%)d,e 1 (2.4%) 19 (30.6%) 7 (35.0%)
 Psychosis, n (%) 0 (0%) 6 (9.8%) 0 (0%)
 ASD, n (%)d,e 0 (0%) 22 (36.1%) 9 (45.0%)
 Medication, n (%)d,e    
  Anti-psychotic 1 (2.4%) 8 (13.1%) 0 (0%)
  Mood stabilizer 1 (3.2%) 7 (11.5%) 6 (30.0%)
  Stimulants 2 (4.9%) 3 (4.9%) 1 (5.0%)
  Other medication 0 (0%) 4 (6.6%) 1 (5.0%)
  No medication 37 (90.2%) 39 (63.9%) 12 (60.0%)
  1. ASD, autism spectrum disorder; nSIPS, number of subjects included in analyses of SIPs sleep variable
  2. aControl > 22qDel (p<0.05)
  3. bControl > 22qDup (p<0.05)
  4. c22qDel > 22qDup (p<0.05)
  5. d22qDel > Control (p<0.05)
  6. e22qDup > Control (p<0.05)